Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00354835 · ClinicalTrials.gov registry record · Phase 3

Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma

A Phase 3 study of Sarcoma and Rhabdomyosarcoma, sponsored by Children's Oncology Group.

Completed
Registry status
Phase 3
Development phase
481
Enrollment target
20
Study locations

NCT00354835 is a Phase 3 study of Sarcoma and Rhabdomyosarcoma that has completed, run by Children's Oncology Group. The registered enrollment target is 481 participants, below the 917-participant average among 122 other Sarcoma trials with a reported enrollment target (48% lower). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00354835, a Phase 3 study of Sarcoma and Rhabdomyosarcoma, has completed, sponsored by Children's Oncology Group.

COMPLETED
Registry status
Phase 3
Development phase
481 participants
Enrollment target
20
Study locations

Study Summary

This randomized phase III trial is studying two different combination chemotherapy regimens to compare how well they work when given together with radiation therapy in treating patients with newly diagnosed rhabdomyosarcoma. Drugs used in chemotherapy, such as vincristine sulfate, dactinomycin, cyclophosphamide, and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with radiation therapy may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective when given together with radiation therapy in treating patients with rhabdomyosarcoma.

Interventions

  • DRUG Cyclophosphamide
  • OTHER Laboratory Biomarker Analysis
  • OTHER Questionnaire Administration
  • DRUG Irinotecan Hydrochloride
  • BIOLOGICAL Dactinomycin

Study Locations (20)

California

  • Kaiser Permanente Downey Medical Center - Downey
  • City of Hope Comprehensive Cancer Center - Duarte
  • Loma Linda University Medical Center - Loma Linda
  • Miller Children's and Women's Hospital Long Beach - Long Beach
  • Children's Hospital Los Angeles - Los Angeles
  • Cedars Sinai Medical Center - Los Angeles
  • Mattel Children's Hospital UCLA - Los Angeles
  • UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
  • Valley Children's Hospital - Madera
  • UCSF Benioff Children's Hospital Oakland - Oakland
  • Kaiser Permanente-Oakland - Oakland
  • Children's Hospital of Orange County - Orange
  • Lucile Packard Children's Hospital Stanford University - Palo Alto
  • Sutter Medical Center Sacramento - Sacramento

Alabama

  • Children's Hospital of Alabama - Birmingham
  • University of Alabama at Birmingham Cancer Center - Birmingham

Arizona

  • Phoenix Childrens Hospital - Phoenix
  • Banner University Medical Center - Tucson - Tucson

Arkansas

  • Arkansas Children's Hospital - Little Rock
  • University of Arkansas for Medical Sciences - Little Rock

Trial Details

FieldValue
Enrollment Target 481 participants
Start Date 2006-12-26
Est. Completion 2022-12-31
Phase Phase 3

Sponsor

Children's Oncology Group

342 total trials

What the Registry Record Tells You About NCT00354835

The ClinicalTrials.gov registry entry for NCT00354835 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 481 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 917-participant average among 122 other Sarcoma trials with a reported enrollment target (48% lower). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Sarcoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.

NCT00354835 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Alabama, Arizona.

Frequently Asked Questions

What is clinical trial NCT00354835 about?

NCT00354835 is a clinical study titled "Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma". This randomized phase III trial is studying two different combination chemotherapy regimens to compare how well they work when given together with radiation therapy in treating patients with newly diagnosed rhabdomyosarcoma. Drugs used in chemotherapy, such as vincristine sulfate, dactinomycin, cycl...

What is the current status of trial NCT00354835?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 481 participants. The study started on 2006-12-26. Estimated completion is 2022-12-31.

What conditions does trial NCT00354835 study?

This clinical trial studies the following conditions: Sarcoma, Rhabdomyosarcoma, Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma.

What interventions are being tested in trial NCT00354835?

The interventions under investigation include: Cyclophosphamide (DRUG), Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER), Irinotecan Hydrochloride (DRUG), Dactinomycin (BIOLOGICAL).

Who is sponsoring clinical trial NCT00354835?

This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00354835 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.